Dr Chowdhury speaks with ecancertv at ESMO 2016 about the effects of enzalutamide, an androgen-receptor antagonist, on men with prostate cancer that has not responded to testosterone-lowering.

Focusing on the side effects of four trials, he describes how the low incidence of fatigue is a comparably minor risk, considering the overall benefits of enzalutamide therapy.

Dr Chowdhury also spoke with ecancer about cancer registries here.